Onconova Therapeutics Inc.

230 articles about Onconova Therapeutics Inc.

• The Leukemia & Lymphoma Society and Onconova Therapeutics Inc. Enter Partnership to Advance Clinical Development of ESTYBON(TM) in High Risk Myelodysplastic Syndrome Patients

  6/1/2010

• Onconova Therapeutics Inc. Announces Presentation of Clinical Proof of Concept of ON 01910.Na in Patients with High Risk Myelodysplastic Syndrome (MDS) at American Society of Hematology 2009 Annual Meeting

  12/7/2009

• Onconova Therapeutics Inc. Announces Presentation of Nonclinical Data on Lead Compound ON 01910.Na and New Jak 2/Bcr-abl Inhibitors at American Association for Cancer Research

  4/22/2009

• Onconova Therapeutics Inc. Announces Initiation of Phase I Clinical Testing for Ex-RAD(TM), a Radioprotective Drug

  1/23/2009

• Onconova Therapeutics Inc. and DoD Collaborators Publish Research Demonstrating Increased Survivability of Previously Lethal Radiation in Mice with New Radioprotective Drug Ex-RAD(TM)

  1/23/2009

• Onconova Therapeutics Inc. Announces Publication of Positive Phase I Results for Lead Anticancer Compound in Journal of Clinical Oncology

  10/28/2008

• Onconova Therapeutics Inc. Announces Presentation of Clinical and Nonclinical Data on Lead Compound ON 01910.Na and New Sulfonamide Compounds at American Association for Cancer Research

  4/11/2008

• Onconova Therapeutics Inc. Announces Presentation of Clinical and Non-Clinical Results for Its Lead Compound ON 01910.Na at American Association for Cancer Research Conference in Los Angeles

  4/16/2007

• Onconova Therapeutics Inc. Release: Data Presented On Anti-Cancer Compound ON 01910.Na At American Society of Clinical Oncology Conference

  6/5/2006

• Michael Hoffman Is Elected Chairman Of The Board For Onconova Therapeutics Inc.

  5/30/2006